+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Vilazodone"

Antidepressants Market Report 2025 - Product Thumbnail Image

Antidepressants Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
From
US Depression Drugs Market, Dosage, Price, Sales Insight 2021-2026 - Product Thumbnail Image

US Depression Drugs Market, Dosage, Price, Sales Insight 2021-2026

  • Report
  • February 2021
  • 420 Pages
  • United States
From
General Anxiety Disorder (GAD) - Pipeline Insight, 2024 - Product Thumbnail Image

General Anxiety Disorder (GAD) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Vilazodone is a prescription medication used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD). It is a serotonin partial agonist and reuptake inhibitor (SPARI) that works by increasing the amount of serotonin in the brain. Vilazodone is a relatively new drug, having been approved by the U.S. Food and Drug Administration (FDA) in 2011. It is available in both immediate-release and extended-release formulations. Vilazodone is used as an adjunct to other treatments for mental disorders, such as psychotherapy and lifestyle changes. It is generally well-tolerated, with the most common side effects being nausea, headache, and insomnia. It is not recommended for use in children or adolescents. The market for mental disorder drugs is highly competitive, with many different companies offering various medications. Some of the major players in the vilazodone market include Allergan, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more